Last checked at 8 Sep 2020 11:40
8 September 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Exercise of Options
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, confirms that 1,350,000 Ordinary Shares of 0.4 pence each ("Ordinary Shares") have been issued by the Company pursuant to an exercise of options over Ordinary Shares for total consideration of £37,800.
Application has been made for the 1,350,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on or around 14 September 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.
Following Admission and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 156,080,349 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
Enquiries:
N4 Pharma plc | |
Nigel Theobald, CEO | Via IFC Advisory |
Luke Cairns, Executive Director | |
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Joint Broker | |
Matthew Johnson/Caroline Rowe (Corporate Finance) | |
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | |
Turner Pope Investments (TPI) Limited | Tel: +44(0)20 3657 0050 |
Joint Broker | |
Andy Thacker | |
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen | Tel: +44(0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.